Ocean Biomedical

Ocean Biomedical Debt Growth

The Year-over-Year Debt Growth of Ocean Biomedical (OCEA) as of Nov 4, 2026 is 34.51 %. In the previous year, Year-over-Year Debt Growth was 463.63 % — a change of -92.56% (lower).

Debt Growth

34.51 %

YoY

-92.56%

Last updated:

Year-over-Year Debt Growth of Ocean Biomedical is 2024 34.51 % . Year-over-Year Debt Growth of Ocean Biomedical was 2023 463.63 % . It decreases by -92.56% lower compared to the previous year.

The Ocean Biomedical Debt Growth history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Debt Growth
Date
Debt Growth
Jan 1, 2023
463.63 USD
Jan 1, 2024
34.51 USD
The Ocean Biomedical Debt Growth history
YEARDebt GrowthYoY
34.51 %-92.56%
463.63 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Ocean Biomedical Stock analysis

What does Ocean Biomedical do? Ocean Biomedical, Inc. develops therapeutic products in oncology, fibrosis, infectious diseases, and inflammation. The company focuses on monoclonal antibodies like Chi3l1-targeting mAbs for non-small cell lung cancer and glioblastoma multiforme. It also offers malaria-related candidates including ODA-570, a vaccine targeting PfSEA-1 and PfGARP, ODA-611, a humanized mAb therapeutic for malaria, and ODA-579, a small molecule malaria therapeutic. These products are developed from research university and medical center assets to accelerate their commercialization. The company monetizes through the development and commercialization of its product candidates. Oncology and malaria-focused therapies represent key segments, with ODA-570, ODA-611, and ODA-579 targeting specific disease areas. Research universities and medical centers are primary collaborators for asset development, providing the foundation for Ocean Biomedical's pipeline. Ocean Biomedical's revenue streams derive from the progression of its therapeutic candidates through development stages. The firm's focus on oncology and malaria therapies drives its product portfolio, with specific candidates like ODA-570, ODA-611, and ODA-579 being central to its commercial strategy. The company accelerates the development of these assets to reach market readiness. Ocean Biomedical is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Ocean Biomedical stock

Year-over-Year Debt Growth of Ocean Biomedical is 34.51 % in 2024.

On Eulerpool you can find the complete historical development of Year-over-Year Debt Growth Ocean Biomedical since 2006 – with annual values, charts, and detailed analysis.

Debt growth measures the percentage change in total debt. Rising debt growth should be compared with revenue and earnings growth to assess sustainability.

To evaluate Year-over-Year Debt Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year Debt Growth.

Year-over-Year Debt Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year Debt Growth's Ocean Biomedical historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Growth — Ocean Biomedical

Revenue GrowthRevenue CAGR 3YRevenue CAGR 5YRevenue CAGR 10YEarnings GrowthEPS GrowthEBIT GrowthEBIT CAGR 3YEBIT CAGR 5YEBIT CAGR 10YDividend GrowthFCF GrowthBook Value GrowthEarnings CAGR 3YEarnings CAGR 5YEarnings CAGR 10YEPS CAGR 3YEPS CAGR 5YEBITDA Growth YoYEBITDA CAGR 3YEBITDA CAGR 5YGross Profit GrowthOCF Growth YoYEmployee GrowthDividend CAGR 3YDividend CAGR 5YDividend CAGR 10YAsset GrowthEquity GrowthDebt GrowthCapEx GrowthFCF CAGR 3YFCF CAGR 5YMarket Cap GrowthShare Count Growth

All Key Metrics — Ocean Biomedical